Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Soligenix

Clinical trials sponsored by Soligenix, explained in plain language.

Soligenix SNGX NASDAQ

A biopharmaceutical company developing treatments for rare diseases and biodefense.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Completed 1 Terminated 1

Light-Activated gel shows promise for rare skin cancer

Disease control Terminated

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

Phase: PHASE3 • Sponsor: Soligenix • Aim: Disease control

Last updated Jul 15, 2026 00:00 UTC